Literature DB >> 33714692

Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.

Gengpeng Lin1, Yangli Liu1, Hui Li2, Shuyin Chen3, Yubiao Guo4.   

Abstract

Entities:  

Keywords:  NTRK fusion; Osimertinib resistance; Targeted therapy

Mesh：

Substances：

Year:  2021        PMID： 33714692     DOI： 10.1016/j.cllc.2021.01.015

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  1 in total

1.  Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.

Authors:  Jiao-Li Wang; Liu-Sheng Wang; Jun-Qi Zhu; Jie Ren; Di Wang; Man Luo
Journal:  Respirol Case Rep       Date:  2022-10-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.